Prelude Therapeutics Inc
Company Stats
- Market Cap
- $312.0M
- as of Sep 30, 2026
- Shares Outstanding
- 79.8M
- Free Float
- 62.5%
Income Statement
- Revenue
- $12.1M
- Operating Income
- -$104.6M
- Net Income
- -$99.5M
- EBITDA
- -$102.9M
Cash Flow
- Free Cash Flow
- -$56.4M
- FCF Yield
- -18.1%
- Owner FCF Yield
- -21.9%
Balance Sheet
- Cash & Equivalents
- $35.3M
Returns & Capital
- SBC, 3Y Avg
- $19.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $12.1M | -$56.4M | -464.3% |
| FY2024 | $7.0M | -$103.7M | -1480.7% |
| FY2023 | — | -$110.6M | — |
| FY2022 | — | -$86.7M | — |
| FY2021 | — | -$85.9M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Utilities Lead Quarterly Dilution as Materials Buybacks Gain